Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.

ABSTRACT:

Background

Obesity and other metabolic comorbidities affect over 10% of patients with breast cancer and are closely related with adverse outcomes. Although metabolic comorbidities among breast cancer patients in low- and middle-income countries are suggested to be lower, only a few studies are currently available. Effective management of metabolic comorbidities in cancer patients has been associated with better outcomes.

Methods

Non-metastatic breast cancer patients (N = 1081) treated in our department (2014-2018) were monitored for the presence of high Body Mass Index (BMI), diabetes or glucose intolerance, dyslipidemia, and hypertension and the development of recurrent metastatic diseases during a median follow-up of 3.9 years.

Results

Glucose intolerance, hypertens

SUBMITTER: Anwar SL 

PROVIDER: S-EPMC8141199 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature